Article Text

Download PDFPDF

4CPS-083 Aging with HIV: optimising pharmacotherapy beyond interactions
  1. J Gallardo-Anciano1,
  2. Y Gonzalez-Perez1,
  3. ME Calvo-Aragüete1,
  4. JR Blanco-Ramos2
  1. 1Hospital Universitario San Pedro, Hospital Pharmacy, Logroño, Spain
  2. 2Hospital Universitario San Pedro, Department of Infectious Diseases, Logroño, Spain


Background Pharmacotherapeutic complexity and potentially inappropriate medication (PIM) negatively affect therapeutic goals in HIV +adult patients and increase frailty and risk of falls. The POINT study carried out in Spain in 2017 alerted polypharmacy and pharmacotherapeutic complexity, and low adherence in HIV +adults.

Purpose To describe treatment complexity, fall-risk-increasing drugs (FRIDs) burden, and the presence of PIM in middle-aged and elderly HIV +patients in our clinical setting.

Material and methods Observational, cross-sectional study was conducted in the referral hospital for HIV infection of our region in April 2018. We selected patients aged ≥45 y. Exclusion criteria: no medication information available in electronic clinical history. Age, gender and active chronic medication were collected. We calculated: overall treatment complexity and complexity due to concomitant one (MRCI-E tool); FRIDs with the most consistent association with a higher risk (antipsychotics, antidepressants, benzodiazepines, loop diuretics, opioids, antiepileptics and polypharmacy, according to the Systematic Review and Meta-Analysis of the EUGMS Task and Finish Group on FRIDs); anticholinergic drug burden (DBI score); and STOPP criteria. Polypharmacy was defined as ≥5 medications. Fix-dose combinations were counted as one drug.

Results A total of 143 HIV +patients were included, all of them on antirretroviral treatment (ART), 92.3% received concomitant non-HIV drugs (non-ART). Median age: 54y (SD 7.6; range 45 to 84y) and 94 (65.7%) male. Eighty-two patients (57.3%) received ≥1 FRID (35.7%≥1 benzodiazepine), 71 (49.7%) had ≥1 anticholinergic drug and at least one STOPP criteria was detected in 55 patients (38.4%).

Abstract 4CPS-083 Table 1

Conclusion The impact of non-HIV drugs on overall pharmacotherapeutic complexity, and the frequent use of PIM in patients≥45 y justifies the need for periodical reassessment of the treatment in order to optimise adequacy and benefit/risk balance.

References and/or acknowledgements POINT study.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.